Clinical Potential: GAMMABODY Platform
Time: 3:15 pm
day: Conference Day Two
Details:
- Generating bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells
- Complementing natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade
- Demonstrating superior efficacy and safety profiles compared to other bispecific T cell engagers approaches
